epidermal growth factor receptor (EGFR), p53 and lymph node metastasis (Rosai, 1996) . Several studies using multivariate analysis indicated that lymph node metastasis is a strong independent prognostic factor (Theunissen et al, 1991; Roder et al, 1994; Tanigawa et al, 1997) . We previously reported that the expression of vascular endothelial growth factor (VEGF) is associated with lymph node metastasis and prognosis in oesophageal cancer (Uchida et al, 1998) . Other reports showed that the expression of matrix metalloproteinases (MMPs) (Shima et al, 1992 ), E-cadherin (Kadowaki et al, 1994; Nakanishi et al, 1997) and p53 (Wang et al, 1994) in primary tumours correlated with lymph node metastasis of oesophageal cancer.
From the aspect of therapy, angiogenesis-mediators and MMPs have been the recent focus of anti-cancer therapy (Gastl et al, 1997) . If we are to use anti-angiogenesis drugs or MMP inhibitors as either adjuvant therapy after surgery or therapy for recurrent tumours, we will clearly require more information regarding the expression of angiogenesis-mediators and MMPs in metastatic tumours. However, few studies describe the expression of these proteins in lymph node metastasis. Therefore, the question remains: do cancer cells continue to express these factors in the lymph nodes?
Previous investigators have described several steps in the metastatic process (Liotta, 1992; Chambers and Matrisian, 1997) . In the process of lymph node metastasis, sequential steps after entry into lymph node would include the following: adhesion to the endothelium of the peripheral sinus, invasion to the parenchyma of the lymph node and sustained growth of cells in the lymph node. What is not yet known, however, is whether the expression of VEGF, MMPs and E-cadherin in cancer cells is changed during these steps of lymph node metastasis.
To answer these questions, we compared the immunohistochemical expression of VEGF, MMP-9, E-cadherin and p53, not only between primary tumours and lymph node metastases of oesophageal cancer, but also between the Early Stage and Late Stage of lymph node metastasis (for a definition of staging see Materials and Methods).
MATERIALS AND METHODS

Samples
We obtained 134 primary tumour samples from 134 patients with oesophageal squamous cell carcinomas from April 1984 to September 1996 treated in the Department of Surgery and Surgical Basic Science, Kyoto University. We divided 134 primary tumour samples into two groups. Group N(-) (n = 37) were resected from patients without synchronous lymph node metastasis or nodal recurrence in follow-up period (≥ 2 years), and Group N(+) Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer (n = 97) were from patients with lymph node metastasis, including one pN0 case with metachronous nodal metastasis.
We obtained 174 lymph node metastasis samples from 35 patients selected from Group N(+). We classified 174 lymph node metastases into two groups, according to the space occupation rate of cancer cells in the maximum cross-section of lymph node (Figure 1 ). There were 56 nodal metastases classified as Early Stage (cancer cells < 50% of lymph node) and 118 metastases classified as Late Stage (≥ 50%). To detect micro-metastasis within the lymph node and to estimate the distribution of cancer cells accurately, we used both haematoxylin and eosin (H&E) stain and anti-cytokeratin immunohistochemistry.
Antibodies
We used five different antibodies, against VEGF, MMP-9, E-cadherin, p53 and cytokeratin. A rabbit polyclonal antibody to VEGF was a generous gift from Dr Ishiwata (Department of Joint Disease, Nippon Medical School, Tokyo, Japan) (Nagashima et al, 1995) . A mouse monoclonal antibody (HECD-1) directed against E-cadherin was a kind gift from Dr Takeichi (Department of Biophysics, Faculty of Science, Kyoto University, Kyoto, Japan). This antibody was used as a 1:100 dilution of culture supernatant of the hybridoma clone described previously (Shimoyama et al, 1989) . The three other mouse monoclonal antibodies were commercially available: anti-hMMP-9 (clone 56-2A4, Fuji Chemical Industries, Ltd, Takaoka, Japan), anti-p53 (clone DO-7, Dako A/S, Glostrup, Denmark), and anti-cytokeratin (clone AE1/AE3, Dako A/S, Glostrup, Denmark). The reliability of the three antibodies has been described elsewhere (Woodcock Mitchell et al, 1982; Vojtesek et al, 1992; Kawahara et al, 1993) .
Immunohistochemistry
The tissue samples were fixed in 10% buffered formalin and embedded in paraffin. Paraffin sections were cut at a thickness of 4-µm and attached to APS-coated glass slides. Sections were dewaxed, hydrated and treated using a high temperature antigen retrieval technique (microwave heating for VEGF and p53, and autoclave heating for MMP-9, E-cadherin and cytokeratin). The endogenous peroxide was blocked with 0.3% hydrogen peroxide in absolute methanol for 30 min. Thirty minutes of incubation with 10% normal horse serum or 10% normal goat serum eliminated non-specific staining. Excess normal serum was removed, replaced by the primary antibody overnight at 4°C. After washing the slides, sections were incubated with a 1:200 dilution of secondary antibody followed by avidin-biotin-peroxidase complex (Vecstain Elite ABC Kit, Vector Laboratories, Inc., Burlingame, CA, USA) for 40 min or 50 min respectively. Subsequently, sections were stained with 0.003% 3,3-diaminobenzidine tetrahydrochloride, 0.005% hydrogen peroxide in 0.05 M Tris-HCl buffer, pH 7.2, counterstained with Mayer's haematoxylin, dehydrated and mounted. 
Evaluation of immunohistochemical staining
VEGF staining was classified into two groups: negative and positive, as previously described (Uchida et al, 1998) . Shima et al (1992) classified the stains of MMPs in oesophageal cancer into three groups. We, however, classified MMP-9 staining into two groups to simplify the data: negative, when the intensity of stain in cancer cells was negative or weaker than normal oesophageal epithelia; positive, when the intensity of staining was equal to or stronger than normal epithelia. According to estimates of positivestaining cell rates, E-cadherin and p53 were divided into two groups: preserved (≥ 50%) and reduced (< 50%), negative (< 10%) and positive (≥ 10%) respectively.
Histology and staging
Histological evaluations were based on the TNM classification proposed by the International Union against Cancer in 1997 (UICC, 1997).
Statistical analysis
Proportional analysis between sample groups was performed with the χ 2 test with Yates' correction and Fisher's exact probability test in 2 × 2 contingency tables. All tests were two-sided, and results were considered significant when P < 0.05.
RESULTS
Expression of VEGF, MMP-9, E-cadherin and p53 in primary tumours
VEGF expression correlated with lymph node metastasis: 48.6% in Group N(-), 74.2% in Group N(+). E-cadherin expression was classified as reduced in 76.3% of Group N(+), compared with 51.4% of Group N(-). This demonstrates the relationship between reduction of E-cadherin in primary tumours and lymph node metastasis. With regard to MMP-9 expression in primary tumours, In three cases, grade of differentiation could not be assessed because almost all or all lesions were limited in epithelia (two; Tis, one; T1). we found no statistical difference between Group N(-) and N(+). The expression of p53 tended to be enhanced in Group N(+), but this was not significant (Figure 2) . Employing anti-cytokeratin immunohistochemistry, we found micro-metastases in 17 lymph nodes, which had been diagnosed as normal by usual pathological examination using H&E staining. Among these metastases, we were able to evaluate the expression of VEGF, MMP-9, E-cadherin and p53 in nine lymph node metastases of seven patients: VEGF (7/9), MMP-9 (8/9), E-cadherin (5/9) and p53 (2/9). The expression of VEGF, MMP-9 and E-cadherin in micro-metastases were roughly consistent with that observed in Early Stage metastasis. 
Clinicopathological background of patients
Patients studied consisted of 110 males and 24 females. The age of patients ranged from 39 to 84 (mean ± standard deviation (s.d.): 63.4 ± 10.0). Gender and pT-factor correlated with lymph node metastasis, but not differentiation grade or age (Table 1) . With regards to the clinicopathological background and the expression of VEGF, MMP-9, E-cadherin and p53, we found no differences between patients selected from Group N(+) in the examination of lymph node and the others (data not shown).
Localization of VEGF, MMP-9, E-cadherin and cytokeratin staining
VEGF stained the vesicle of cancer cells. Immunoreactivity against MMP-9 was found in the basal layers of normal oesophageal epithelia, macrophages, granulocytes, fibroblasts and the cytoplasm of cancer cells. E-cadherin expression was detected only in the cytomembrane, or both in the cytomembrane and the cytoplasm of cancer cells, and in the cytomembrane of normal epithelia.
This anti-cytokeratin antibody (AE1/AE3) recognizes many types of cytokeratin. Staining was detected in the cytoplasm of cancer cells and normal oesophageal epithelia. The staining of the cancer cells was intense and covered almost the entire cells in all but one of the 35 patients whose lymph nodes were examined.
Heterogeneity between lymph node metastases
Frequently, patients with cancer have plural lymph node metastases. To ascertain whether all lymph node metastasis of a patient express equal amounts of VEGF, MMP-9, E-cadherin or p53, we compared the expression of these proteins among the metastases of each patient. The number of lymph node metastases obtained from the same patient ranged from 1 to 19 (mean ± s.d.: 4.74 ± 4.08). Fifteen patients had plural lymph node metastases in Early Stage, whereas 23 patients had Late Stage plural metastases. Table 2 shows the number of these patients with inter-nodal heterogeneity of VEGF, MMP-9, E-cadherin and p53 expression (i.e. patients whose metastases varied with respect to the expression of these proteins). A high rate of overall inter-nodal heterogeneity is expected because the expression of VEGF, MMP-9 and E-cadherin changes from Early Stage to Late Stage. However, we found inter-nodal heterogeneity of expression of all four factors in each stage, ranging from 13.3% to 53.3%.
DISCUSSION
The question addressed by the present study was whether the expression of VEGF, MMP-9, E-cadherin and p53 remains stable, or changes in the process of lymph node metastasis of oesophageal cancer. The main finding of this study is that the expression of VEGF, MMP-9, E-cadherin and p53 changes not only between the primary tumour and lymph node metastasis, but also between early-and late-stages of lymph node metastasis.
The pattern of change is different for each of these factors in the process of lymph node metastasis, and suggests where each factor might play an important role in the metastatic process. The pattern of VEGF is that VEGF expression of Group N(+) is much greater than that of Group N(-); however, the expression of VEGF is suppressed with the progression of metastatic stage. We and other investigators showed that over-expression of VEGF in primary tumours correlates with lymph node metastasis in oesophageal cancer and other tumours (Maeda et al, 1996; Moriyama et al, 1997; Ohta et al, 1997; Uchida et al, 1998) . VEGF is a multifunctional molecule that has been implicated in vasculogenesis (Carmeliet et al, 1996; Ferrara et al, 1996) , endothelial cell proliferation and migration (Senger et al, 1993) , vascular permeability (Roberts and Palade, 1995) , and stromal degradation through the activation of some proteolytic enzymes involved in tumour invasiveness and angiogenesis (Ferrara, 1996) . However, it is not yet known which of VEGF's functions play an important role in promoting lymph node metastasis. On the other hand, it is generally believed that angiogenesis is required in secondary tumour progression (Folkman, 1990) . Our data shows that in Early Stage metastasis VEGF is prominent when compared to Late Stage, and suggests that development in Late Stage tumour growth may be VEGF-independent, whereas the initial metastatic event may be VEGF-dependent or at least correlative.
The pattern of MMP-9 expression is that the MMP-9-positive rate is elevated in Early Stage of lymph node metastasis, whereas MMP-9 expression in primary tumour (both Group N(-) and N(+)) and Late Stage lymph node metastasis is lower. In our data, MMP-9 expression in primary tumour does not correlate with lymph node metastasis or any other clinicopathological factors (data not shown). The balance of activators and inhibitors, such as TIMP-1, regulates activity of MMP-9 (Liotta and Stetler Stevenson, 1991) . In Early Stage metastatic lymph nodes, lymphocytes or macrophages surrounding cancer cells also produce MMP-9, and constitute a greater volume than do the metastatic cells. Therefore, it is unknown whether MMP-9 produced by cancer cells disturbs the balance between proteinases and inhibitors. However, our present findings suggest that cancer cells in Early Stage may react more strongly to a new microenvironment than cancer cells in Late Stage.
The pattern for E-cadherin is that the suppression of E-cadherin expression in primary tumour correlates with lymph node metastasis, and this result is compatible with findings of numerous other studies. In metastatic lesion, E-cadherin expression tends to be somewhat restored in Early Stage, but suppressed again in Late Stage. Cell dissociation and acquisition of cell motility are believed to affect the initial steps in the metastatic process. Therefore, suppressed expression or dysfunction of the cadherin-catenin complex might trigger the escape of cancer cells from the primary tumour. E-cadherin expression in metastatic lesion has been described by several authors, and became somewhat controversial (Schipper et al, 1991; Bongiorno et al, 1995; Jawhari et al, 1997; von Wasielewski et al, 1997) . Shiozaki speculates that unstable E-cadherin reduction plays a role in terms of detachment and release from the primary lesion in the process of vessel invasion; however, when it comes to the establishment of actual metastasis, the opposite appears to be more favourable from the standpoint of attachment and growth as metastatic foci (Shiozaki et al, 1996) . Our data also suggest that E-cadherin expression might offer some advantages in Early Stage of lymph node metastasis.
In this study, p53 expression was unchanged from Early Stage to Late Stage, whereas VEGF, MMP-9 and E-cadherin was downregulated. These data indicate that the down-regulation of VEGF, MMP-9 and E-cadherin expression does not depend on nonspecific reduction of overall protein synthesis of cancer cells. We previously reported the intimate relationship between VEGF expression and p53 mutation (Uchida et al, 1998) . However, in this study, we found an inverse correlation between VEGF and p53 in lymph node metastasis. This finding suggests that VEGF would be regulated by pathways other than p53 in lymph node metastasis.
The mechanism of this regulation of VEGF, MMP-9, E-cadherin and p53 is unknown. Accumulation of gene abnormalities is generally thought to provide metastatic potential to cancer cells, and worsen prognosis (Vogelstein et al, 1989; Bland et al, 1995; Shimada et al, 1997) . However, this study demonstrates that the acquired expression of malignant factors is not maintained through the end-stage of metastasis, but in fact changes. As the metastatic stage in the lymph node is advanced, the normal structure of the lymph node is gradually destroyed, and function of lymph nodes might be suppressed or lost. We suggest that the microenvironment (e.g. extracellular matrix, growth factors, cytokines and host defence) around cancer cells might change as cancer cells proliferate, and that as a consequence, the interaction between the cancer cells and the microenvironment might also change. In this study, we found inter-nodal heterogeneity as well as intra-nodal heterogeneity. Inter-nodal heterogeneity might be the result of not only heterogeneity of the cancer cell clones but also the alternative reaction of cancer cells to different microenvironments.
With regard to the staging of lymph node metastasis, Kurokawa (1970) divided lymph node metastases into three grades in an experimental model of lymph node metastasis. Shigetomi et al (1992) later modified Kurokawa's classification into four stages by observation of numerous serial sections, using the staging as an index of the metastatic potential (i.e. stage 0: cancer cells are limited in perinodal lymphatic vessels; stage 1: cancer cells are seen only in peripheral sinus; stage 2: cancer cells invade the cortex of lymph node, but not beyond 50%; stage 3: more than 50% of lymph node is occupied by cancer cell). However, to the best of our knowledge, no one has yet reported the correlation between the expression of cancer-related factors and the extent of lymph node metastasis. In order to simplify the data, we categorized the extent of lymph node metastases roughly into two stages by the space occupation rate of cancer cells (cut-off point: 50%).
From a therapeutic aspect, angiogenesis-mediators and MMPs have recently been the focus of targeted anticancer therapy (Gastl et al, 1997) . If anti-angiogenesis drugs or MMP inhibitors are to be used as adjuvant therapy after surgery or therapy for recurrent tumours, information regarding the angiogenesis-mediators and MMPs in residual cancer cells will be required to judge the indication for the therapy. This study suggests that drugs directly inhibiting VEGF or MMPs might be more effective in micrometastasis or in cancer cells in Early Stage than in Late Stage.
In conclusion, the expression of VEGF, MMP-9 and E-cadherin are down-regulated from Early Stage to Late Stage of lymph node metastasis. Future analysis of the mechanisms responsible for these phenomena will be necessary.
